West Pharmaceutical Services WST · NYSE
$383.83 +0.21% (+$0.81)
Summary
63 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- It has raised its dividend 11 years in a row and pays out only 11% of profit.
- It holds more cash than debt: $435.8M against $312.1M.
- It earns 16 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 4.2% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 47.8 USD for 1 USD of yearly profit. Over the last five years it was 43.7 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.4% a year over 5 years. Over the last 3 years it grew by 2.1% a year. For the next fiscal year analysts expect revenue to grow by 9.8%. Earnings per share fell by 4.2% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 63 USD
- Research and development 2.2 USD
- Sales and administration 14 USD
- Taxes and other 3.7 USD
- Net profit 17 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.23%
- Paid out of profit
- 11%
- Raised in a row
- 11 years
You receive $0.88 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $412.83 is 7.6% above today's price. 82% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Proprietary Products 81%
- Contract Manufactured Products 19%
By region
- UNITED STATES 43%
- Other Europe Countries 15%
- GERMANY 12%
- Other Countries 11%
- IRELAND 11%
- Other 7.4%
Proprietary Products brings in 81% of revenue. Contract Manufactured Products grew fastest, by 3.1% a year.
Segments in detail